• 1
    Quinn GE, Gilbert C, Darlow BA, Zin A. Retinopathy of prematurity: an epidemic in the making. Chin Med J (Engl) 2010; 123: 292937.
  • 2
    Fanaroff AA, Stoll BJ, Wright LL et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196: 147 e18.
  • 3
    Serenius F, Ewald U, Farooqi A, Holmgren PA, Hakansson S, Sedin G. Short-term outcome after active perinatal management at 23–25 weeks of gestation. A study from two Swedish tertiary care centres. Part 2: infant survival. Acta Paediatr 2004; 93: 10819.
  • 4
    Allegaert K, de Coen K, Devlieger H. Threshold retinopathy at threshold of viability: the EpiBel study. Br J Ophthalmol 2004; 88: 23942.
  • 5
    Austeng D, Kallen KB, Ewald UW, Jakobsson PG, Holmstrom GE. Incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol 2009; 127: 13159.
  • 6
    The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984; 102: 11304.
  • 7
    An International Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 2005; 123: 9919.
  • 8
    Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics 1988; 81: 697706.
  • 9
    Early Treatment for Retinopathy of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 168494.
  • 10
    Peng CJ, Lee KL, Ingersoll GM. An introduction to logistic regression analysis and reporting. J Educ Res 2002; 96: 11.
  • 11
    Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84: 7782.
  • 12
    Gilbert C, Fielder A, Gordillo L et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005; 115: e51825.
  • 13
    Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 2005; 115: 9906.
  • 14
    Markestad T, Kaaresen PI, Ronnestad A et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115: 128998.
  • 15
    Weber C, Weninger M, Klebermass K et al. Mortality and morbidity in extremely preterm infants (22 to 26 weeks of gestation): Austria 1999–2001. Wien Klin Wochenschr 2005; 117: 7406.
  • 16
    Good WV, Hardy RJ, Dobson V et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005; 116: 1523.
  • 17
    Fortes Filho JB, Eckert GU, Procianoy L, Barros CK, Procianoy RS. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. Eye (Lond) 2009; 23: 2530.
  • 18
    Shah VA, Yeo CL, Ling YL, Ho LY. Incidence, risk factors of retinopathy of prematurity among very low birth weight infants in Singapore. Ann Acad Med Singapore 2005; 34: 16978.
  • 19
    Saunders RA, Donahue ML, Christmann LM et al. Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1997; 115: 6048.
  • 20
    Yu VY. Is neonatal intensive care justified in all preterm infants? Croat Med J 2005; 46: 74450.
  • 21
    Moriette G, Rameix S, Azria E et al. [Very premature births: dilemmas and management. Part 1. Outcome of infants born before 28 weeks of postmenstrual age, and definition of a gray zone]. Arch Pediatr 2010; 17: 51826.
  • 22
    Seri I, Evans J. Limits of viability: definition of the gray zone. J Perinatol 2008; 28 (Suppl. 1): S48.
  • 23
    Lui K, Bajuk B, Foster K et al. Perinatal care at the borderlines of viability: a consensus statement based on a NSW and ACT consensus workshop. Med J Aust 2006; 185: 495500.
  • 24
    Darlow BA. The limits of perinatal viability: grappling with the ‘grey zone’. Med J Aust 2006; 185: 4779.
  • 25
    Akkoyun I, Oto S, Yilmaz G et al. Risk factors in the development of mild and severe retinopathy of prematurity. J AAPOS 2006; 10: 44953.
  • 26
    Chen M, Citil A, McCabe F et al. Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity. Neonatology 2010; 99: 12532.
  • 27
    Fortes Filho JB, Eckert GU, Valiatti FB, Dos Santos PG, da Costa MC, Procianoy RS. The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP). Graefes Arch Clin Exp Ophthalmol 2010; 248: 893900.
  • 28
    Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 2005; 5: 18.
  • 29
    Schwarz EC, Grauel EL, Wauer RR. No increase of incidence of retinopathy of prematurity and improvement of its outcome in a university perinatal centre level iii – a prospective observational study from 1978 to 2007. Klin Monbl Augenheilkd 2010; 228: 20819.